ArticleSurgery open science2026
Analysis of an acute care surgery service performing temporal artery biopsy for suspected giant cell arteritis.
Article in Surgery open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temporal artery biopsy (TAB) for suspected giant cell arteritis (GCA) represents an infrequent but important inpatient consultation for acute care surgery (ACS) services. Given the morbidity associated with delayed treatment, corticosteroids are often initiated before biopsy, raising questions about the diagnostic utility and impact of TAB in contemporary practice. We performed a review of all inpatient TABs completed by an ACS service at a tertiary center between March 2015 and January 2024 to characterize case volume, pathology results, and influence of biopsy findings on corticosteroid management. Sixty-four patients underwent TAB, the majority of whom were elderly and female, with visual symptoms and headache being the most common presenting complaints. Nearly all patients were initiated on high-dose corticosteroids prior to biopsy, with a median of two days between ACS consultation and procedure. Pathologic findings confirmed GCA in 10% of cases, with additional biopsies demonstrating intimal fibroplasia or equivocal inflammatory changes. Despite widespread steroid initiation, biopsy results influenced discharge management, as patients with negative pathology were more likely to undergo corticosteroid tapering prior to or shortly after discharge. The median American College of Rheumatology 1990 classification score was three, with just over half of patients meeting criteria for GCA. No TABs were performed during 2020, but biopsy volume increased substantially in the post-COVID period. These findings suggest that ACS services play an important role in the diagnostic evaluation of suspected GCA. Although corticosteroid therapy is frequently initiated prior to biopsy, TAB continues to yield clinically meaningful information that informs subsequent management decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.